Better Regulation of Industry-Sponsored Clinical Trials is Long Overdue

Stossel T. P. , “Regulating Academic-Industrial Research Relationships – Solving Problems or Stifling Progress?” New England Journal of Medicine 353, no. 10 (2005): 1060–1065.

Lasser K. E. , “Timing of New Black Box Warnings and Withdrawals for Prescription Medications,” JAMA 287, no. 17 (2002): 2215–2220.

Moore T. J. , “Serious Adverse Drug Events Reported to the Food and Drug Administration, 1998–2005,” Archives of Internal Medicine 167, no. 16 (2007): 1752–1759.

Collins J. and Porras J. I. , Built to Last: Successful Habits of Visionary Companies (New York: HarperCollins, 2004).

Wynia M. K. , “Public Health, Public Trust and Lobbying,” American Journal of Bioethics 7, no. 6 (2007): 4–7, at6.

Brody H. , Hooked: Ethics, the Medical Profession and the Pharmaceutical Industry (Lanham: Rowman & Littlefield Publishers, Inc.: 2007): at 342.

Ridker P. M. and Torres J. , “Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000–2005,” JAMA 295, no. 19 (2006): 2270–2276.

Als-Nielsen B. , “Association of Funding and Conclusions in Randomized Drug Trials”, JAMA 290, no. 7 (2003): 921–928; Djulbegovic B. , “The Uncertainty Principle and Industry-Sponsored Research”, The Lancet 356, no. 9230 (2000): 635–638.

Bero L. , “Factors Associated with Findings of Published Trials of Drug-Drug Comparisons: Why Some Statins Appear More Efficacious Than Others,” Public Library of Science 4, no. 6 (2007): 1–10.

Id.

Lexchin J. , “Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review”, BMJ 326, no. 7400 (2006): 1167–1170.

Bekelman J. E. , “Scope and Impact of Financial Conflicts of Interest in Biomedical Research”, JAMA 289, no. 4 (2003): 454–456.

Djulbegovic B. , “The Uncertainty Principle and Industry-Sponsored Research,” The Lancet 356, no. 9230 (2000): 635–638; see Lexchin , supra note 11; Als-Nielsen , supra note 8; Kjaergard L. L. and Gluud C. , “Funding, Disease Area, and Internal Validity of Hepatobiliary Randomized Controlled Trials”, American Journal of Gastroenterology 97, no. 11 (2002): 2708–2713.

See Als-Nielsen , supra note 8.

Moher D. , “Assessing the Quality of Reports of Randomized Controlled Trials: Implications for the Conduct of MetaAnalyses”, Health Technology Assessment 3, no. 12 (1999), available at <http://www.hta.ac.uk/fullmono/mon312.pdf> (last visited July 2, 2009).

Chan A. W. , “Empirical Evidence for Selective Reporting of Outcomes in Randomized Trials: Comparison of Protocols to Published Articles,” JAMA 291 (2004): 2457–2465; Rennie D. , “Thyroid Storm”, JAMA 277, no. 15 (1997): 1238–1243.

Smith R. , “Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies,” Public Library of Science Medicine 2, no. 5 (2005): 364–366.

Laine C. , “Clinical Trial Registration: Looking Back and Moving Ahead,” JAMA 298, no. 3 (2007): 93–94.

Blumenthal D. , “Withholding Research Results in Academic Life Science: Evidence from a National Survey of Faculty,” JAMA 277, no. 15 (1997): 1224–1228.

See Lexchin , supra note 11.

Bero L. A. and Rennie D. , “Influences on the Quality of Published Drug Studies,” International Journal of Technology Assessment in Health Care 12, no. 2 (1996): 209–237; Safer D. J. , “Design and Reporting Modifications in Industry-Sponsored Comparative Psychopharmacology Trials”, Journal of Nervous and Mental Disease 190, no. 9 (2002): 583–592; see Smith , supra note 17.

Johansen H. K. and G0tzsche P. C. , “Problems in the Design and Reporting of Trials of Antifungal Agents Encountered During Meta-analysis,” JAMA 282, no. 18 (1999): 1752–1759.

Id.

Psaty B. M. Weiss N. S. and Furberg C. D. , “Recent Trials in Hypertention: Compelling Science or Commercial Speech?” JAMA 295, no. 14 (2006): 1704–1706.

See Safer , supra note 21.

See Bero , supra note 9.

See Brody , supra note 6.

Lind T. , “Esomeprazole Provides Improved Acid Control vs. Omeprazole in Patients with Symptoms of Gastro-Oesophageal Reflux Disease,” Alimentary Pharmacology & Therapeutics 14, no. 7 (2000): 861–867.

See Djulbegovic , supra note 13.

Psaty B. M. and Rennie D. , “Clinical Trial Investigators and Their Prescribing Patterns,” JAMA 295, no. 23 (2006): 2787–2790.

Brophy J. M. , “Selling Safety — Lessons from Muraglitazar,” JAMA 294, no. 20 (2005): 2633–2635 at 20.

Kaul S. and Diamond G. A. , “Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials,” Annals of Internal Medicine 145, no. 1 (2006): 62–69.

Ross D. B. , “The FDA and the Case of Ketek,” New England Journal of Medicine 356, no. 16 (2007): 1601–1604.

Farahani P. , “Clinical Data Gap between Phase III Clinical Trials (Pre-Marketing) and Phase IV (Post-Marketing) Studies: Evaluation of Etanercept in Rheumatoid Arthritis,” Canadian Journal of Clinical Pharmacology, 12, no. 3 (2005).

See Brophy , supra note 31.

Zinman , “The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes,” Annals of Internal Medicine 146, no. 7 (2007): 477–485. (cited in Malozowski S. , “Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions”, Annals of Internal Medicine 146, no. 7 [2007]: 477–485).

See Psaty and Rennie , supra note 30.

Curfman G. D. Morrisey S. and Drazen J. M. , “Expression of Concern Reaffirmed,” New England Journal of Medicine 354, no. 11 (2006): 1193.

Hrachovec J. B. and Mora M. , “Reporting of 6-month vs 12-month Data in a Clinical Trial of Celecoxib,” JAMA 286, no. 19 (2001): 2398–2399; Malhotra S. , “COX-2 Inhibitors: A CLASS Act or Just VIGORously Promoted?” MedGenMed 6 (2004), available at <http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15208519#r25> (last visited June 22, 2009).

Reid I. R. , “Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A randomized Controlled trial”, Journal of Clinical Endocrinology and Metabolism 92, no. 7 (2007): 2446–2452.

Rossouw J. E. , “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial,” JAMA 288, no. 3 (2002): 321–333.

Epstein A. E. , “Mortality Following Ventricular Arrhythmia Suppression by Encainide, Flecainide, and Moricizine after Myocardial Infarction: The Original Design Concept of the Cardiac Arrhythmia Suppression Trial (CAST),” JAMA 270, no. 20 (1993): 2451–2455.

Lago R. M. Singh P. P. and Nesto R. W. , “Congestive Heart Failure and Cardiovascular Death in Patients with Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomised Clinical Trials,” The Lancet 370, no. 9593 (2007): 1129–1136.

Kessler D. A. , “Therapeutic-Class Wars — Drug Promotion in a Competitive Marketplace,” New England Journal of Medicine 331, no. 20 (1994): 1350–1353.

See Psaty and Rennie , supra note 30.

See Kessler , supra note 44.

Caulfield T. A. , “Legal and Ethical Issues Associated with Patient Recruitment in Clinical Trials: The Case of Competitive Environment,” Health Law Review 13, nos. 2–3 (2005): 58–61.

See Brody , supra note 6, at 120.

Eichenwald K. and Kolata G. , “Drug Trials Hide Conflicts for Doctors,” New York Times, May 16, 1999, available at <http://www.nytimes.com/1999/05/16/business/drug-trials-hide-conflicts-for-doctors.html> (last visited July 2, 2009).

Rennie D. and Flanagin A. “Authorship! Authorship! Guests, Ghosts, Grafters, and the Two-Sided Coin,” JAMA 271, no. 6 (1994): 469–471.

See Eichenwald and Kolata , supra note 49.

See Ross , supra note 33.

See Eichenwald and Kolata , supra note 49; Harris G. and Roberts J. , “After Sanctions, Doctors Get Drug Company Pay,” New York Times, June 3, 2007, available at <http://www.nytimes.com/2007/06/03/health/03docs.html> (last visited July 2, 2009); Ross , supra note 33.

See Eichenwald and Kolata , supra note 49.

See Harris and Roberts , supra note 53.

See Als-Nielsen , supra note 8.

Holmes D. R. , “Conflict of Interest,” American Heart Journal 147, no. 2 (2004): 228–237.

See Brody , supra note 6, at 2.

Melander H. , “Evidence B(i)ased Medicine — Selective Reporting from Studies Sponsored by Pharmaceutical Industry: Review of Studies in New Drug Applications,” BMJ 326, no. 7400 (2003): 1171–1173.

Knox K. S. , “Reporting and Disseminatino of Industry versus Non-Profit Sponsored Economic Analyses of Six Novel Drugs Used in Oncology,” Annals of Oncology 11, no. 12 (2000): 1591–1595.

See Brody , supra note 6, at 119.

Schafer A , “Biomedical Conflicts of Interest: A Defence of the Sequestration Thesis-Learning from the Cases of Nancy Olivieri and David Healy,” Journal of Medical Ethics 30, no. 1 (2004): 8–24.

See Rennie and Flanagin , supra note 50.

Puckner W. A. and Leech P. , “The Introduction of New Drugs,” JAMA 93, no. 21 (1929): 1627–1630.

Ross J. S. , “Guest Authorship and Ghostwriting in Publications Related to Rofecoxib,” JAMA 299, no. 15 (2008): 1800–1812.

See Brody , supra note 6, at 138.

PricewaterhouseCoopers' Health Research Institute, “Recapturing the Vision: Integrity Driven Performance in the Pharmaceutical Industry,” 2005, available at <http://www.pwc.com/extweb/pwcpublications.nsf/docid/ee74bacb-6de454768525702a00630cff> (last visited June 22, 2009).

Lenzer J. , “Scandals Have Eroded US Public's Confidence in Drug Industry,” BMJ 329, no. 7460 (2004): 247; Dolliver M. , “Mark Dolliver's Takes: Big Pharma Is Shifty”, May 28, 2007, available at <http://www.adweek.com/aw/magazine/article_display.jsp?vnu_content_id=1003590894> (last visited June 22, 2009).

See Blumenthal supra note 19.

See Laine supra note 18.

For a recent example of an apparent post-hoc, selective analysis, see “Clinical Trial Registry of What?” posted anonymously, available at <http://clinpsyc.blogspot.com/2007/10/clinical-trial-registry-of-what.html> (last visited June 22, 2009).

Wood A. Grady C. and Emanuel E. J. , “Regional Ethics Organizations for Protection of Human Research Participants,” Nature Medicine 10, no. 12 (2004): 1283–1288.

Brody , supra note 6; Krimsky S. , Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? (Lanham, MD: Rowman and Littlefield, 2003).

Wilensky G. R. , “Developing a Center for Comparative Effectiveness,” The Commonwealth Fund, available at <http://www.commonwealthfund.org/usr_doc/Wilensky_develctrcompareffect_967_itl.pdf?section=4039> (last visited June 22, 2009).